ProKidney Corp. Holds Annual Stockholder Meeting
Ticker: PROK · Form: 8-K · Filed: May 31, 2024 · CIK: 1850270
| Field | Detail |
|---|---|
| Company | Prokidney Corp. (PROK) |
| Form Type | 8-K |
| Filed Date | May 31, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-meeting, corporate-governance, shareholder-vote
Related Tickers: PKNY
TL;DR
PKNY held its annual meeting, shareholders voted on directors, auditors, and executive pay.
AI Summary
On May 30, 2024, ProKidney Corp. filed an 8-K report detailing the results of its Annual Meeting of Stockholders held on May 29, 2024. Key proposals included the election of two Class II directors, ratification of the appointment of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2024, and an advisory vote on executive compensation.
Why It Matters
This filing provides transparency on shareholder decisions regarding board composition, auditor selection, and executive pay, which can influence investor confidence and company governance.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure of meeting results and does not present new financial or operational risks.
Key Players & Entities
- ProKidney Corp. (company) — Registrant
- May 30, 2024 (date) — Date of Report
- May 29, 2024 (date) — Date of Annual Meeting
- PricewaterhouseCoopers LLP (company) — Independent Registered Public Accounting Firm
FAQ
What were the key proposals voted on at the ProKidney Corp. Annual Meeting of Stockholders?
The key proposals included the election of two Class II directors, the ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and an advisory vote on executive compensation.
When was the ProKidney Corp. Annual Meeting of Stockholders held?
The Annual Meeting of Stockholders was held on May 29, 2024.
Who was appointed as ProKidney Corp.'s independent registered public accounting firm?
PricewaterhouseCoopers LLP was ratified as ProKidney Corp.'s independent registered public accounting firm for the fiscal year ending December 31, 2024.
What is the fiscal year end for which PricewaterhouseCoopers LLP was appointed?
PricewaterhouseCoopers LLP was appointed for the fiscal year ending December 31, 2024.
What type of vote was held regarding executive compensation?
An advisory vote on executive compensation was held.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 13.7 · Accepted 2024-05-31 16:19:43
Key Financial Figures
- $0.0001 — h registered Class A ordinary shares, $0.0001 par value per share PROK The Nasdaq
Filing Documents
- prok-20240530.htm (8-K) — 56KB
- 0000950170-24-067341.txt ( ) — 171KB
- prok-20240530.xsd (EX-101.SCH) — 25KB
- prok-20240530_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On May 30, 2024, ProKidney Corp. (the "Company") held its 2024 Annual General Meeting of Shareholders (the "Annual General Meeting"). The matters voted on at the Annual General Meeting and the votes cast with respect to each such matter are set forth below: (1) Based on the following results of the voting, the Company's shareholders elected the nominees listed below to the Company's Board of Directors, each to serve for a three-year term to expire at the Company's annual general meeting of shareholders in 2027 and until their successors are duly elected and qualified: Director Nominee For Against Abstain Broker Non Votes Jennifer Fox 180,074,590 1,649,737 218 4,943,486 Jos Ignacio Jimnez Santos 180,893,693 830,587 265 4,943,486 (2) The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified based on the following results of the voting: For Against Abstain Broker Non Votes 182,470,555 4,195,327 2,149 –
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROKIDNEY CORP. Date: May 31, 2024 By: /s/ James Coulston James Coulston Chief Financial Officer